The True Cost of Falsified Medicine
A recent review and meta-analysis highlights the huge impact of fake and substandard drugs on health, trust in healthcare, and the economy
Roisin McGuigan |
Around one in every eight essential medicines in lower income countries may be of low quality, or an outright fake. This was the conclusion of a review and met-analysis performed on relevant studies in five databases, including Pubmed and Embase, which allowed researchers to examine over 350 previous studies, which between them tested more than 4,000,000 drug samples.
“I recently transitioned to the School of Pharmacy at the University of North Carolina at Chapel Hill, where it struck me how important medicine quality is for protecting population health. Ensuring that medicine is doing what it’s intended to do is critical to a trusted healthcare system. We wanted to know how large of a problem poor quality medicines is,” says Sachiko Ozawa, first author of the review (1).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine